Karen Liu has been active in China healthcare venture investment since 2005. She is a founding partner of 3E Bioventures Capital, a healthcare focused venture capital firm. With a focus on solving unmet medical and health needs, 3E invests in frontier health technologies, including innovative and first-in-class therapies as well as disruptive and cross-disciplinary innovations in medical devices and diagnostics.
Prior to 3E Bioventures, Dr. Karen Liu was a partner of Kaiwu Capital and Managing Director at CRCI Capital, always covering healthcare investing.
Karen Liu received her Ph.D in Immunology from Harvard University, Master of Medical Sciences degree from Harvard University, and Bachelor of Sciences degree from Cornell University. She also received an EMBA degree from CKGSB – Chungkong Graduate School of Business in China.